Premium
Role of geranylgeranylacetone as non‐toxic HSP 70 inducer in liver surgery: clinical application
Author(s) -
Tashiro Seiki,
Miyake Hidenori,
Rokutan Kazuhito
Publication year - 2018
Publication title -
journal of hepato‐biliary‐pancreatic sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.63
H-Index - 60
eISSN - 1868-6982
pISSN - 1868-6974
DOI - 10.1002/jhbp.549
Subject(s) - inducer , heat shock protein , clinical trial , medicine , liver transplantation , clinical efficacy , hsp70 , randomized controlled trial , pharmacology , biology , transplantation , biochemistry , gene
Heat shock proteins ( HSP s) are rapidly synthesized into cells in response to various types of physical or chemical insults and induce potent resistance to the stressors. A stress‐inducible HSP 70 is not expressed in normal conditions, but once HSP 70 is excessively induced under various environmental stresses, HSP 70‐expressing cells can survive even under lethal conditions. In this review, we focused on the potential role of HSP s particularly HSP 70 in liver surgery. A non‐toxic HSP 70 inducer, geranylgeranylacetone ( GGA ), has been introduced to exert a potent cytoprotective action against liver injury after ischemia/reperfusion, massive hepatectomy and liver transplantation in animal experiments. We have tried to explain possible therapeutic benefits of GGA in liver surgery. However, any dependable clinical application has not been done. One of the reasons is that any randomized clinical trial has not being carried out in clinical cases. Therefore, we have advocated the national scale randomized clinical trial for dependable clinical application of GGA .